Last reviewed · How we verify

NCT06578104

PULSED AF Post-Approval Study

Recruiting now Last updated 27 March 2026
What this trial tests

trial testing PulseSelect™ PFA system in Atrial Fibrillation in 580 participants. Currently enrolling.

Timeline
4 November 2024
Primary endpoint
1 June 2026
1 June 2029

Quick facts

Lead sponsorMedtronic Cardiac Ablation Solutions
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment580
Start date4 November 2024
Primary completion1 June 2026
Estimated completion1 June 2029
Sites16 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medtronic Cardiac Ablation Solutions — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Medtronic Cardiac Ablation Solutions trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06578104.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing